AGP Executive Report
Last update: 41 minutes agoOncology & Drug R&D: Plinabulin plus docetaxel is moving through a global phase 3 DUBLIN-4 trial for advanced non-squamous NSCLC after immune checkpoint inhibitor progression, with sites planned in China and elsewhere and overall survival as the primary endpoint. Public Health & Research: A new genome-wide meta-analysis points to a BACH2–NRF2 pathway as a potential target to activate fetal hemoglobin, independent of BCL11A, raising hopes for sickle cell and thalassemia therapies. Cancer Burden Watch: A study comparing pancreatic cancer burden in China vs the US (1990–2023) finds lower age-standardized mortality in China but highlights shifting risk factors, with fasting plasma glucose rising as a major driver. Infectious Disease: Chinese researchers report a previously unknown tick-borne virus (ALTNV) linked to fever, GI symptoms, fatigue, and low platelets, including in patients who test negative for the known Dabie bandavirus. Health Policy & Care Delivery: A Stanford study on opioid tapering emphasizes patient control—participants could slow, pause, or stop reductions—showing many reduced opioid use without worsening pain. Wellness & Lifestyle: Hilton’s 2027 trends report flags growing demand for water-based and thermal wellness experiences, especially when they’re social.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.
Perspectify News
